Hosonuma Rie, Fujiwara Shin-Ichiro, Sasazaki Miyuki, Hirata Yuji, Yamamoto Chihiro, Uesawa Mitsuyo, Oh Iekuni, Matsuyama Tomohiro, Mori Masaki, Ozawa Keiya, Muroi Kazuo
Division of Cell Therapy, Jichi Medical University Hospital.
Rinsho Ketsueki. 2012 Apr;53(4):469-71.
In our facility, three patients developed tacrolimus (TAC)-induced renal dysfunction after allogeneic hemopoietic stem cell transplantation, although trough levels of TAC were within therapeutic ranges. They received an oral agent of slow-release TAC once a day instead of a regular form oral TAC twice a day. Following treatment with the prolonged-release agent, serum creatinine levels decreased and graft-versus-host disease (GVHD) did not occur. Use of this slow-release formulation may avoid toxic peak concentrations of TAC without the development of GVHD.
在我们的机构中，三名患者在异基因造血干细胞移植后出现了他克莫司（TAC）诱导的肾功能障碍，尽管TAC的谷浓度在治疗范围内。他们改为每天服用一次口服缓释TAC制剂，而不是常规剂型的口服TAC每日两次。使用缓释制剂治疗后，血清肌酐水平下降，且未发生移植物抗宿主病（GVHD）。使用这种缓释制剂可能避免TAC的毒性峰值浓度，同时不会发生GVHD。
